Bayer Backs Hot Flashes Drug For Blockbuster Status
As German Major Posts Decent Q3 Figures
The menopause drug elinzanetant, which has just gone into Phase III, has joined Kerendia, Verquvo and Nubeqa as a candidate that Bayer believes has a peak sales potential of more than €1bn.
